Crotamiton에 대한 Mechanism_Of_Action 정보 Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Lidocaine에 대한 Mechanism_Of_Action 정보 Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Miconazole에 대한 Mechanism_Of_Action 정보 Miconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Miconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.
Pharmacology
Crotamiton에 대한 Pharmacology 정보 Crotamiton is usually used to treat pruritis (itching of the skin) caused by scabies or sunburn. Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Due to this cooling effect it is also effective for the relief of sunburn. The drug is also believed to kill scabies through an unknown mechanism. Lidocaine에 대한 Pharmacology 정보 Lidocaine is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidocaine appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidocaine in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide. Miconazole에 대한 Pharmacology 정보 Miconazole is an anti-fungal medication related to fluconazole (Diflucan), ketoconazole (Nizoral), itraconazole (Sporanox), and clotrimazole (Lotrimin, Mycelex). It is used either on the skin or in the vagina for fungal infections. Miconazole was approved by the FDA in 1974. Miconazole prevents fungal organisms from producing vital substances required for growth and function. This medication is effective only for infections caused by fungal organisms. It will not work for bacterial or viral infections.
Metabolism
Crotamiton에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available Lidocaine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2D6 (CYP2D6) Miconazole에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2C9 (CYP2C9)Cytochrome P450 2D6 (CYP2D6)
Protein Binding
Crotamiton에 대한 단백결합 정보 Not Available Lidocaine에 대한 단백결합 정보 60-80% Miconazole에 대한 단백결합 정보 Not Available
Half-life
Crotamiton에 대한 반감기 정보 Not Available Lidocaine에 대한 반감기 정보 109 minutes Miconazole에 대한 반감기 정보 Not Available
Absorption
Crotamiton에 대한 Absorption 정보 10 % absorbed when applied locally. Lidocaine에 대한 Absorption 정보 Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Miconazole에 대한 Absorption 정보 Not Available
Pharmacokinetics
Lidocaine의 약물동력학자료
효과발현시간 (1회 bolus 용량으로서) : 45-90초
작용지속시간 : 10-25분
분포 (Vd) : 많은 요인에 따라 변화되며, 울혈성 심부전과 간질환에서는 분포용적이 감소됨
단백결합 : 60-80%, α1-acid glycoprotein과 결합
대사 : 간에서 90% 대사
활성형 대사체인 monoethylglycinexylidide(MEGX)와 glycinexylidide(GX)가 축적되어 중추신경계 독성을 유발할 수 있다.
반감기 (biphasic) : 울혈성 심부전, 간질환, 쇼크, 중증의 신질환에서 증가
초기 : 7-30분
말기 : 영아, 미숙아 : 3.2시간, 성인 : 1.5-2시간
Miconazole nitrate의 약물동력학자료
단백결합 : 91-93%
대사 : 간대사
반감기 : Multiphasic
초기 : 40분
Secondary : 126분
Terminal : 24시간
소실 : 50%까지 변배설, 1% 미만이 미변화체로 신배설
Biotransformation
Crotamiton에 대한 Biotransformation 정보 Not Available Lidocaine에 대한 Biotransformation 정보 Primarily hepatic. Miconazole에 대한 Biotransformation 정보 Not Available
Toxicity
Crotamiton에 대한 Toxicity 정보 Not Available Lidocaine에 대한 Toxicity 정보 The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. Miconazole에 대한 Toxicity 정보 Oral, mouse: LD50 = 3800 mg/kg; Oral, rat: LD50 = 3 gm/kg. Ingestion of the amounts of the components contained in a tube of cream are unlikely to produce overdosage and toxic effects.
Drug Interactions
Crotamiton에 대한 Drug_Interactions 정보 Acetohexamide The beta-blocker decreases the symptoms of hypoglycemiaChlorpropamide The beta-blocker decreases the symptoms of hypoglycemiaCimetidine Cimetidine increases the effect of the beta-blockerClonidine Increased hypertension when clonidine stoppedDisopyramide The beta-blocker increases toxicity of disopyramideGliclazide The beta-blocker decreases the symptoms of hypoglycemiaGlipizide The beta-blocker decreases the symptoms of hypoglycemiaGlisoxepide The beta-blocker decreases the symptoms of hypoglycemiaGlibenclamide The beta-blocker decreases the symptoms of hypoglycemiaGlycodiazine The beta-blocker decreases the symptoms of hypoglycemiaInsulin The beta-blocker decreases the symptoms of hypoglycemiaLidocaine The beta-blocker increases the effect and toxicity of lidocainePropafenone Propafenone increases the effect of beta-blockerRepaglinide The beta-blocker decreases the symptoms of hypoglycemiaRifampin Rifampin decreases the effect of the metabolized beta-blockerTelithromycin Telithromycin may possibly increase metoprolol effectTolazamide The beta-blocker decreases the symptoms of hypoglycemiaTolbutamide The beta-blocker decreases the symptoms of hypoglycemiaAmobarbital The barbiturate decreases the effect of metabolized beta-blockerAprobarbital The barbiturate decreases the effect of metabolized beta-blockerButalbital The barbiturate decreases the effect of metabolized beta-blockerButabarbital The barbiturate decreases the effect of metabolized beta-blockerButethal The barbiturate decreases the effect of metabolized beta-blockerDihydroquinidine barbiturate The barbiturate decreases the effect of metabolized beta-blockerHeptabarbital The barbiturate decreases the effect of metabolized beta-blockerHexobarbital The barbiturate decreases the effect of metabolized beta-blockerMethohexital The barbiturate decreases the effect of metabolized beta-blockerMethylphenobarbital The barbiturate decreases the effect of metabolized beta-blockerPentobarbital The barbiturate decreases the effect of metabolized beta-blockerPhenobarbital The barbiturate decreases the effect of metabolized beta-blockerPrimidone The barbiturate decreases the effect of metabolized beta-blockerQuinidine barbiturate The barbiturate decreases the effect of metabolized beta-blockerSecobarbital The barbiturate decreases the effect of metabolized beta-blockerTalbutal The barbiturate decreases the effect of metabolized beta-blockerCitalopram The SSRI increases the effect of the beta-blockerEscitalopram The SSRI increases the effect of the beta-blockerFluoxetine The SSRI increases the effect of the beta-blockerSertraline The SSRI increases the effect of the beta-blockerParoxetine The SSRI increases the effect of the beta-blockerDihydroergotamine Ischemia with risk of gangreneDihydroergotoxine Ischemia with risk of gangreneErgonovine Ischemia with risk of gangreneErgotamine Ischemia with risk of gangreneMethysergide Ischemia with risk of gangreneVerapamil Increased effect of both drugsHydralazine Increased effect of both drugsDiltiazem Increased risk of bradycardiaEpinephrine Hypertension, then bradycardiaFenoterol AntagonismFormoterol AntagonismIsoproterenol AntagonismOrciprenaline AntagonismPirbuterol AntagonismPrazosin Risk of hypotension at the beginning of therapyProcaterol AntagonismSalbutamol AntagonismSalmeterol AntagonismTerbutaline AntagonismIbuprofen Risk of inhibition of renal prostaglandinsIndomethacin Risk of inhibition of renal prostaglandinsPiroxicam Risk of inhibition of renal prostaglandins Lidocaine에 대한 Drug_Interactions 정보 Not Available Miconazole에 대한 Drug_Interactions 정보 Warfarin Vaginal miconazole increases the anticoagulant effectAcenocoumarol Vaginal miconazole increases the anticoagulant effectDicumarol Vaginal miconazole increases the anticoagulant effectAnisindione Vaginal miconazole increases the anticoagulant effect
Crotamiton에 대한 Description 정보 Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol. Lidocaine에 대한 Description 정보 A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem] Miconazole에 대한 Description 정보 An imidazole antifungal agent that is used topically and by intravenous infusion. [PubChem]
Dosage Form
Crotamiton에 대한 Dosage_Form 정보 Cream Topical Lidocaine에 대한 Dosage_Form 정보 Aerosol TopicalAerosol, metered TopicalCream TopicalGel TopicalJelly TopicalJelly UrethralLiquid BuccalLiquid DentalLiquid InfiltrationLiquid IntravenousLiquid OralLiquid TopicalLotion TopicalOintment TopicalSolution InfiltrationSolution IntramuscularSolution IntravenousSolution OralSolution TopicalSpray TopicalSwab Topical Miconazole에 대한 Dosage_Form 정보 Aerosol TopicalCream IntravaginalCream TopicalSuppository Intravaginal
Drug Category
Crotamiton에 대한 Drug_Category 정보 Antiparasitic AgentsAntipruriticsPesticidesScabicides Lidocaine에 대한 Drug_Category 정보 AnestheticsAnesthetics, LocalAnti-Arrhythmia AgentsAntiarrhythmic Agents Miconazole에 대한 Drug_Category 정보 Antifungal Agents
Smiles String Canonical
Crotamiton에 대한 Smiles_String_canonical 정보 CCN(C(=O)C=CC)C1=CC=CC=C1C Lidocaine에 대한 Smiles_String_canonical 정보 CCN(CC)CC(=O)NC1=C(C)C=CC=C1C Miconazole에 대한 Smiles_String_canonical 정보 ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
Smiles String Isomeric
Crotamiton에 대한 Smiles_String_isomeric 정보 CCN(C(=O)\C=C\C)C1=CC=CC=C1C Lidocaine에 대한 Smiles_String_isomeric 정보 CCN(CC)CC(=O)NC1=C(C)C=CC=C1C Miconazole에 대한 Smiles_String_isomeric 정보 ClC1=CC(Cl)=C(CO[C@@H](CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
InChI Identifier
Crotamiton에 대한 InChI_Identifier 정보 InChI=1/C13H17NO/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10H,5H2,1-3H3 Lidocaine에 대한 InChI_Identifier 정보 InChI=1/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)/f/h15H Miconazole에 대한 InChI_Identifier 정보 InChI=1/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2
Chemical IUPAC Name
Crotamiton에 대한 Chemical_IUPAC_Name 정보 N-ethyl-N-(2-methylphenyl)but-2-enamide Lidocaine에 대한 Chemical_IUPAC_Name 정보 2-diethylamino-N-(2,6-dimethylphenyl)acetamide Miconazole에 대한 Chemical_IUPAC_Name 정보 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
Drug-Induced Toxicity Related Proteins
DOCA 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Aquaporin-2 Drug:DOCA Toxicity:hypertension. [바로가기]LIDOCAINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:glucose-regulated protein Drug:lidocaine Toxicity:intestinal disorder. [바로가기]Replated Protein:Alkaline phosphatase Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기]Replated Protein:C-reactive protein Drug:lidocaine Toxicity:fever. [바로가기]Replated Protein:C-reactive protein Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기]Replated Protein:Alpha-1-acid glycoprotein Drug:lidocaine Toxicity:lidocaine tolerance. [바로가기]Replated Protein:Gamma-glutamyltranspeptidase Drug:lidocaine Toxicity:fever. [바로가기]Replated Protein:Alkaline phosphatase Drug:lidocaine Toxicity:fever. [바로가기]Replated Protein:Gamma-glutamyltranspeptidase Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기]
사용자컨텐츠
항목
내용
최근정보수정일 2024-06-05
본 수정일 정보는 허가정보 이외의 기타정보 수정일을 의미하므로, 허가정보수정일은 본문에 표기된 날짜를 참조하시기 바랍니다.
알림
상세정보는 식품의약품안전처의 제품허가사항을 토대로 작성되었으며 요약정보는 상세정보 및 기타문헌을 기반으로 드럭인포에서 편집한 내용입니다. 제품허가사항의 목차와 다소 상이할 수 있습니다.
경고
드럭인포 의약학술정보는 식품의약품안전처의 제품허가사항, 학술문헌, 제약회사 제공정보 등을 근거로 작성된 참고 정보입니다.
정보의 정확성을 위해 노력하고 있으나 편집상의 오류, 허가사항 변경, 추가적인 학술연구 또는 임상연구 발표 등으로 인해 발생하는 문제에 대해 드럭인포는
책임을 지지 않습니다. 자세한 내용은 “책임의 한계 및 법적고지”를 참조해 주십시오.
반드시 제조·수입사, 판매사, 의사, 약사에게 최종적으로 확인하시기 바랍니다.
전화: 02-3486-1061 ㅣ 이메일: webmaster@druginfo.co.kr
전문/일반
